13F reference period
Q2 2026
Security Snapshot
First Tracks Biotherapeutics, Inc. - COMMON STOCK (TRAX) Institutional Ownership
CUSIP: 337185102
13F Institutional Holders and Ownership History from Q2 2026 to Q3 2026
Institutions Reporting
149
Shares (Excl. Options)
34.09M
Full value: 34,089,134 · shares · 30 Jun 2026Price
$20.12
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- TRAX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 34,089,134
- Total 13F value
- $685,819,544
- Portfolio coverage rank
- 0%
- Share change
- +32,992,508
- Value change
- +$663,755,317
- Number of holders
- 149
- Underlying class
- Common Stock
- Shares outstanding
- 42,017,813
- SEC-reported price per share
- $31.68
Latest holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- TRAX - First Tracks Biotherapeutics, Inc. - COMMON STOCK is tracked under CUSIP 337185102.
- 149 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- The headline uses Q2 2026 reported holdings.
- Quarter-over-quarter comparison is unavailable because the immediately preceding quarter is missing.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 149 institutions filings for Q2 2026.
Security key
337185102
13F reference period
Q2 2026
13F holders
149
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
TRAX full holder history
First Tracks Biotherapeutics, Inc. SEC filings
First Tracks Biotherapeutics, Inc. company facts
First Tracks Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 337185102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
TRAX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +152% | $199,668,649 | +$134,593,906 | 6,302,672 | +207% | FMR LLC | 30 Oct 2026 |
| TCG Crossover GP II, LLC | 8.3% | $101,364,593 | 2,895,304 | Chen Yu | 30 Jun 2026 | |||
| BlackRock, Inc. | 7.2% | +28% | $90,672,283 | +$22,649,598 | 2,558,473 | +33% | BlackRock, Inc. | 30 Sep 2026 |
| Sirenia Capital Management LP | 7.2% | $87,377,153 | 2,495,777 | Sirenia Capital Management LP | 30 Jun 2026 | |||
| Affinity Asset Advisors, LLC | 5.8% | $71,140,740 | 2,032,012 | Affinity Asset Advisors, LLC | 30 Jun 2026 |
As of 30 Jun 2026,
149
institutional investors reported holding
shares of
First Tracks Biotherapeutics, Inc. - COMMON STOCK (TRAX).
This represents
81%
of the company’s total
outstanding shares.
34.09M
Full value: 34,089,134 · shares · 30 Jun 202642.02M
Full value: 42,017,813 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
67%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.6% | 3,174,519 | 3.2% | $63,871,322 | |
| TCG Crossover Management, LLC | 6.9% | 2,895,304 | 1.4% | $58,253,516 | |
| FMR LLC | 4.9% | 2,054,127 | 0% | $41,329,045 | |
| Affinity Asset Advisors, LLC | 4.8% | 2,032,012 | 2% | $40,884,081 | |
| BlackRock, Inc. | 4.7% | 1,963,541 | 0% | $39,506,446 | |
| Trails Edge Capital Partners, LP | 3.6% | 1,514,000 | 4.8% | $30,461,680 | |
| STATE STREET CORP | 3.6% | 1,512,896 | 0% | $30,439,468 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 1,451,909 | 0% | $29,212,409 | |
| Jupiter Topco LLC | 2.6% | 1,091,464 | 0% | 0.01% | $21,960,368 |
| Vestal Point Capital, LP | 2.4% | 1,013,000 | 0.48% | $20,381,560 | |
| Woodline Partners LP | 2.2% | 917,176 | 0.06% | $18,453,581 | |
| Sanofi | 2% | 821,917 | 3.1% | $16,536,970 | |
| MORGAN STANLEY | 1.9% | 781,534 | 0% | $15,724,464 | |
| 683 Capital Management, LLC | 1.8% | 750,000 | 1.4% | $15,090,001 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.7% | 729,000 | 0.02% | $14,667,480 | |
| Balyasny Asset Management L.P. | 1.7% | 714,948 | 0.03% | $14,384,754 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 702,087 | 0% | $14,128,648 | |
| BANK OF AMERICA CORP /DE/ | 1.5% | 647,962 | 0% | $13,036,996 | |
| STEMPOINT CAPITAL LP | 1.5% | 622,723 | 2.2% | $12,529,187 | |
| Palo Alto Investors LP | 1.4% | 603,489 | 1.7% | $12,142,199 | |
| Sofinnova Investments, Inc. | 1.3% | 565,199 | 0.61% | $11,371,804 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3% | 546,992 | 0% | $11,005,479 | |
| GOLDMAN SACHS GROUP INC | 1.2% | 487,213 | 0% | $9,802,725 | |
| Point72 Asset Management, L.P. | 0.97% | 408,330 | 0.01% | $8,215,600 | |
| UBS Group AG | 0.74% | 310,886 | 0% | $6,255,026 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Headline period
Q2 2026
Rows shown
1-2 of 2